Li XY, et al. - Researchers sought to determine the 10-year survival outcomes between radiotherapy and chemoradiotherapy in stage II nasopharyngeal carcinoma (NPC). They randomly assigned patients with stage II NPC to radiotherapy (RT) arm (n = 114) or to concurrent chemoradiotherapy (CCRT) arm (n = 116) with a concurrent weekly cisplatin regimen. CCRT arm displayed significant improvements in overall survival (OS) (83.6% vs 65.8%), progression-free survival (76.7% vs 64.0%), cancer-specific survival (86.2% vs 71.9%), distant-metastasis-free survival (94.0% vs 83.3%) with a median follow-up of 125 months. T2N1 population mainly showed the survival benefits earned by CCRT. Despite more acute toxic effects in CCRT arm, comparable late toxicities and treatment-associated deaths events were evident between the two arms. Ten-year outcomes establish that OS of stage II patients could be improved with CCRT without adding late toxicities compared with conventional RT.